ARCHIVES

Tivozanib Trumps Sorafenib In 1st-Line Renal Cancer Study

This article is from The Cancer Letter archive.

Vol. 35 No. 5 | May 25, 2012

Download PDF Visit The Full Archive

Related Articles

NCI Critic Epstein Resurfaces TO Blast ‘Cancer Establishment’

February 14, 1992

Kington Named Acting NIH Director.

November 14, 2008

Sanofi: Zaltrap Price Reflects Competing Drugs In Second-Line Metastatic Colon Cancer

November 1, 2012

Senate Committee Passes Bill To Speed FDA Approval Of Follow-On Biologics.

June 29, 2007

Newell Describes Progress To House, Senate Subcommittees

March 25, 1977

Scientist’s Interpretation Of Meta-Analysis On ESAs Turns 180 Degrees Over 72 Hours.

June 8, 2007